View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMerrimack Pharmaceuticals 配当と自社株買い配当金 基準チェック /06Merrimack Pharmaceuticals配当金を支払った記録がありません。主要情報n/a配当利回り-0.8%バイバック利回り総株主利回り-0.8%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新お知らせ • May 11Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024Merrimack Pharmaceuticals, Inc. announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024.すべての更新を表示Recent updatesお知らせ • May 21Merrimack Pharmaceuticals Files Form 15Merrimack Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share.お知らせ • May 11Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024Merrimack Pharmaceuticals, Inc. announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024.お知らせ • May 01Merrimack Pharmaceuticals Intends to Voluntary Delist Class A Common StockPursuant to the Plan of Dissolution, on April 30, 2024, Merrimack Pharmaceuticals, Inc. notified The Nasdaq Stock Market LLC (Nasdaq") of its intention to voluntarily delist its shares of Class A common stock, par value $0.01 per share (the Common Stock") from Nasdaq and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act"). The Company currently estimates a cash dividend for the initial liquidating distribution in the range of $14.92 to $15.15 per share. Such range is an estimate and the actual cash dividend amount, which is expected to be announced on or about May 8, 2024, may fall outside of this range and is subject To Approve the Plan of Dissolution by stockholders at the Special Meeting. The Company intends to file with the SEC a Form 25 on or about May 10, 2024 to effect the delisting and deregistration of the Common Stock from Nasdaq under Section 12(b) of the Exchange Act, if the proposed liquidation and dissolution of the Company is approved by stockholders at the Special Meeting. The delisting will become effective later in May. Upon the effectiveness of the Form 25, the Company also intends to file a Form 15 with the SEC on or about May 20, 2024 to suspend the Company's reporting obligations under Sections 13 and 15(d) of the Exchange Act and deregister the Common Stock under Section 12(b) of the Exchange Act.分析記事 • Feb 14We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash BurnJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...お知らせ • Nov 10Merrimack Pharmaceuticals, Inc. Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaMerrimack Pharmaceuticals, Inc. announced that Ipsen, SA issued a press release reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a treatment of first line metastatic pancreatic ductal adenocarcinoma (mPDAC). The Ipsen press release indicates that the trial “met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and key secondary efficacy outcome of progression-free survival also showed significant improvement over the comparator arm. The safety profile of Onivyde in the NAPOLI 3 trial was consistent with those observed in the previous phase I/II mPDAC study.” Ipsen indicated in its update that it intends to file a supplemental New Drug Application with the U.S. Food and Drug Administration for Onivyde in combination with oxaliplatin plus 5- fluorouracil/leucovorin for the treatment of patients with previously untreated mPDAC following the Fast Track Designation granted in 2020.分析記事 • Sep 23Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 04Merrimack Pharmaceuticals GAAP EPS of -$0.04Merrimack Pharmaceuticals press release (NASDAQ:MACK): Q2 GAAP EPS of -$0.04. As of June 30, 2022, Merrimack had cash and cash equivalents of $13.4 million, compared to $14.2 million as of December 31, 2021.Recent Insider Transactions • Mar 22President recently bought US$61k worth of stockOn the 14th of March, Gary Crocker bought around 10k shares on-market at roughly US$6.05 per share. In the last 3 months, they made an even bigger purchase worth US$80k. Gary has been a buyer over the last 12 months, purchasing a net total of US$439k worth in shares.分析記事 • Mar 19Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Recent Insider Transactions • Feb 22President recently bought US$80k worth of stockOn the 17th of February, Gary Crocker bought around 13k shares on-market at roughly US$6.17 per share. This was the largest purchase by an insider in the last 3 months. Gary has been a buyer over the last 12 months, purchasing a net total of US$399k worth in shares.Recent Insider Transactions • Jan 27Co-Founder & Independent Director recently bought US$61k worth of stockOn the 24th of January, Ulrik Nielsen bought around 14k shares on-market at roughly US$4.24 per share. This was the largest purchase by an insider in the last 3 months. This was Ulrik's only on-market trade for the last 12 months.分析記事 • May 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To GrowEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent Insider Transactions • Mar 27President recently bought US$55k worth of stockOn the 24th of March, Gary Crocker bought around 9k shares on-market at roughly US$6.39 per share. This was the largest purchase by an insider in the last 3 months. Gary has been a buyer over the last 12 months, purchasing a net total of US$202k worth in shares.Is New 90 Day High Low • Mar 05New 90-day low: US$6.44The company is down 9.0% from its price of US$7.07 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.分析記事 • Feb 22Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...Is New 90 Day High Low • Feb 11New 90-day high: US$8.70The company is up 135% from its price of US$3.71 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.分析記事 • Jan 01Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, Merrimack...Is New 90 Day High Low • Nov 13New 90-day low: US$3.71The company is down 14% from its price of US$4.30 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.お知らせ • Jul 04Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from Russell Microcap Value IndexMerrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from Russell Microcap Value Index決済の安定と成長配当データの取得安定した配当: MACKの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: MACKの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Merrimack Pharmaceuticals 配当利回り対市場MACK 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (MACK)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (MACK) (最長3年)n/a注目すべき配当: MACKは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: MACKは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: MACKの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: MACKが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/05/21 23:26終値2024/05/17 00:00収益2024/03/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Merrimack Pharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Michael UlzBairdRachel McMinnBofA Global ResearchDaniel BrimsCantor Fitzgerald & Co.5 その他のアナリストを表示
お知らせ • May 11Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024Merrimack Pharmaceuticals, Inc. announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024.
お知らせ • May 21Merrimack Pharmaceuticals Files Form 15Merrimack Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share.
お知らせ • May 11Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024Merrimack Pharmaceuticals, Inc. announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024.
お知らせ • May 01Merrimack Pharmaceuticals Intends to Voluntary Delist Class A Common StockPursuant to the Plan of Dissolution, on April 30, 2024, Merrimack Pharmaceuticals, Inc. notified The Nasdaq Stock Market LLC (Nasdaq") of its intention to voluntarily delist its shares of Class A common stock, par value $0.01 per share (the Common Stock") from Nasdaq and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act"). The Company currently estimates a cash dividend for the initial liquidating distribution in the range of $14.92 to $15.15 per share. Such range is an estimate and the actual cash dividend amount, which is expected to be announced on or about May 8, 2024, may fall outside of this range and is subject To Approve the Plan of Dissolution by stockholders at the Special Meeting. The Company intends to file with the SEC a Form 25 on or about May 10, 2024 to effect the delisting and deregistration of the Common Stock from Nasdaq under Section 12(b) of the Exchange Act, if the proposed liquidation and dissolution of the Company is approved by stockholders at the Special Meeting. The delisting will become effective later in May. Upon the effectiveness of the Form 25, the Company also intends to file a Form 15 with the SEC on or about May 20, 2024 to suspend the Company's reporting obligations under Sections 13 and 15(d) of the Exchange Act and deregister the Common Stock under Section 12(b) of the Exchange Act.
分析記事 • Feb 14We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash BurnJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
お知らせ • Nov 10Merrimack Pharmaceuticals, Inc. Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaMerrimack Pharmaceuticals, Inc. announced that Ipsen, SA issued a press release reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a treatment of first line metastatic pancreatic ductal adenocarcinoma (mPDAC). The Ipsen press release indicates that the trial “met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and key secondary efficacy outcome of progression-free survival also showed significant improvement over the comparator arm. The safety profile of Onivyde in the NAPOLI 3 trial was consistent with those observed in the previous phase I/II mPDAC study.” Ipsen indicated in its update that it intends to file a supplemental New Drug Application with the U.S. Food and Drug Administration for Onivyde in combination with oxaliplatin plus 5- fluorouracil/leucovorin for the treatment of patients with previously untreated mPDAC following the Fast Track Designation granted in 2020.
分析記事 • Sep 23Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 04Merrimack Pharmaceuticals GAAP EPS of -$0.04Merrimack Pharmaceuticals press release (NASDAQ:MACK): Q2 GAAP EPS of -$0.04. As of June 30, 2022, Merrimack had cash and cash equivalents of $13.4 million, compared to $14.2 million as of December 31, 2021.
Recent Insider Transactions • Mar 22President recently bought US$61k worth of stockOn the 14th of March, Gary Crocker bought around 10k shares on-market at roughly US$6.05 per share. In the last 3 months, they made an even bigger purchase worth US$80k. Gary has been a buyer over the last 12 months, purchasing a net total of US$439k worth in shares.
分析記事 • Mar 19Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Recent Insider Transactions • Feb 22President recently bought US$80k worth of stockOn the 17th of February, Gary Crocker bought around 13k shares on-market at roughly US$6.17 per share. This was the largest purchase by an insider in the last 3 months. Gary has been a buyer over the last 12 months, purchasing a net total of US$399k worth in shares.
Recent Insider Transactions • Jan 27Co-Founder & Independent Director recently bought US$61k worth of stockOn the 24th of January, Ulrik Nielsen bought around 14k shares on-market at roughly US$4.24 per share. This was the largest purchase by an insider in the last 3 months. This was Ulrik's only on-market trade for the last 12 months.
分析記事 • May 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To GrowEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Recent Insider Transactions • Mar 27President recently bought US$55k worth of stockOn the 24th of March, Gary Crocker bought around 9k shares on-market at roughly US$6.39 per share. This was the largest purchase by an insider in the last 3 months. Gary has been a buyer over the last 12 months, purchasing a net total of US$202k worth in shares.
Is New 90 Day High Low • Mar 05New 90-day low: US$6.44The company is down 9.0% from its price of US$7.07 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
分析記事 • Feb 22Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Is New 90 Day High Low • Feb 11New 90-day high: US$8.70The company is up 135% from its price of US$3.71 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.
分析記事 • Jan 01Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, Merrimack...
Is New 90 Day High Low • Nov 13New 90-day low: US$3.71The company is down 14% from its price of US$4.30 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.
お知らせ • Jul 04Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from Russell Microcap Value IndexMerrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from Russell Microcap Value Index